Cytogen/Cellcor $20 mil. merger and $12 mil. subscription offering enhance Cytogen's cash position.
CYTOGEN/CELLCOR $20 MIL. MERGER AND $12 MIL. SUBSCRIPTION OFFERING will enhance Cytogen's cash position while bringing in Cellcor's proprietary technology with at least one product in late-stage development. The companies jointly announced the signing of a definitive merger agreement June 16. Cytogen was advised in the merger by Smith Barney, and Cellcor was aided by First Boston.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth